Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study

[1]  A. Fomsgaard,et al.  Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine , 2022, JAMA network open.

[2]  M. Mulligan,et al.  Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease , 2022, The Lancet Rheumatology.

[3]  G. Kaplan,et al.  Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis , 2022, The Lancet Rheumatology.

[4]  S. Nejentsev,et al.  Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies , 2022, The Lancet Rheumatology.

[5]  R. R. Hagen,et al.  Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study , 2022, The Lancet Rheumatology.

[6]  A. Iagnocco,et al.  EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update , 2022, Annals of the Rheumatic Diseases.

[7]  D. Segev,et al.  Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease , 2022, The Lancet Rheumatology.

[8]  C. Berking,et al.  Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS–CoV‐2 in an Unvaccinated Cohort , 2021, Arthritis & rheumatology.

[9]  T. Harrer,et al.  Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.

[10]  Lindsay N. Carpp,et al.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[11]  Gregory F. Wu,et al.  Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors , 2021, Med.

[12]  C. Hirzel,et al.  Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study , 2021, The Lancet Rheumatology.

[13]  Gregory F. Wu,et al.  Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 , 2021, Annals of Internal Medicine.

[14]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[15]  J. Sparks,et al.  Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases , 2021, Annals of the Rheumatic Diseases.

[16]  M. Boers,et al.  Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies , 2021, The Lancet Rheumatology.

[17]  M. Neurath,et al.  COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses , 2021, The Lancet Rheumatology.

[18]  J. Vekemans,et al.  Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[19]  Mimi Y. Kim,et al.  Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort , 2021, The Lancet Rheumatology.

[20]  M. Neurath,et al.  Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.

[21]  D. Segev,et al.  High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.

[22]  M. Neurath,et al.  Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.

[23]  C. Berking,et al.  SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases , 2021, Annals of the Rheumatic Diseases.

[24]  P. Hoff,et al.  Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort , 2021, Annals of the Rheumatic Diseases.

[25]  J. Sparks,et al.  SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease , 2021, Annals of the Rheumatic Diseases.

[26]  A. Ogdie,et al.  COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes , 2020, Arthritis & rheumatology.

[27]  C. Berking,et al.  Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion , 2020, Nature Communications.

[28]  A. Neimann,et al.  Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York , 2020, The New England journal of medicine.